November 4, 2021 12:25 PM EDT
Manufacturing

Hic­cup in man­u­fac­tur­ing will cause Gen­Sight to re­peat the process for reti­nal gene ther­a­py; Den­dreon an­nounces col­lab­o­ra­tion with Shore­line Bio­sciences

Josh Sullivan

Four months af­ter a gene ther­a­py Phase III tri­al for reti­nal neu­rode­gen­er­a­tive dis­eases from French biotech Gen­Sight failed de­spite im­prove­ment in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Ei­sai ter­mi­nates Phase 3 tri­al of Dravet drug, cit­ing re­cruit­ment chal­lenges

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Boston Phar­ma­ceu­ti­cals hits Phase 2 goals as it tries to keep up with MASH com­peti­tors

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times